Grade 3 to 5 adverse events
| . | Patients (N = 48) . | ||
|---|---|---|---|
| Grade 3, no. (%) . | Grade 4, no. (%) . | Grade 5, no. (%) . | |
| Hematologic toxicities | |||
| Neutropenia | 6 (13) | 10 (21) | |
| Lymphopenia | 16 (33) | 21 (44) | |
| Thrombocytopenia | 6 (13) | 3 (6) | |
| Anemia | 5 (10) | ||
| Febrile neutropenia* | 2 (4) | ||
| Nonhematologic toxicities | |||
| Rash | 12 (25) | ||
| Infection (nonneutropenic)† | 3 (6) | 1 (2) | 1 (2) |
| Nausea | 2 (4) | ||
| Vomiting | 1 (2) | ||
| Fever | 1 (2) | ||
| Hypotension | 2 (4) | ||
| Hypertension | 1 (2) | ||
| Hypokalemia | 1 (2) | ||
| Hyponatremia | 3 (6) | ||
| Hypophosphatemia | 3 (6) | ||
| Hyperuricemia | 1 (2) | ||
| Pancreatitis | 1 (2) | ||
| Fatigue | 1 (2) | ||
| . | Patients (N = 48) . | ||
|---|---|---|---|
| Grade 3, no. (%) . | Grade 4, no. (%) . | Grade 5, no. (%) . | |
| Hematologic toxicities | |||
| Neutropenia | 6 (13) | 10 (21) | |
| Lymphopenia | 16 (33) | 21 (44) | |
| Thrombocytopenia | 6 (13) | 3 (6) | |
| Anemia | 5 (10) | ||
| Febrile neutropenia* | 2 (4) | ||
| Nonhematologic toxicities | |||
| Rash | 12 (25) | ||
| Infection (nonneutropenic)† | 3 (6) | 1 (2) | 1 (2) |
| Nausea | 2 (4) | ||
| Vomiting | 1 (2) | ||
| Fever | 1 (2) | ||
| Hypotension | 2 (4) | ||
| Hypertension | 1 (2) | ||
| Hypokalemia | 1 (2) | ||
| Hyponatremia | 3 (6) | ||
| Hypophosphatemia | 3 (6) | ||
| Hyperuricemia | 1 (2) | ||
| Pancreatitis | 1 (2) | ||
| Fatigue | 1 (2) | ||